Abstract
Glycogen phosphorylase (GP) has been firmly proved as an important target for treatment of type 2 diabetes. With the rapid increase of type 2 diabetic patients recently, it is becoming an interesting field to discover GP inhibitor for potential antidiabetic drugs. As GP is a typical allosteric protein with several key inhibitor binding sites including the inhibitor, the catalytic, the allosteric and the new allosteric sites, the research works were mainly focused on compounds that can bind these sites and show selective inhibitory effect. This paper mainly reviewed the advances in the design of inhibitors for different binding sites of GP and aimed at providing readers with some useful hints towards more effective GP inhibitors.
Keywords: Glycogen phosphorylase, inhibitors, binding sites, type 2 diabetes, allosteric protein, metabolism, gluconeogenesis, cyclodextrins, van der Waals bonds, riboflavin
Current Enzyme Inhibition
Title:Recent Advances in Design of Glycogen Phosphorylase Inhibitors
Volume: 7 Issue: 4
Author(s): Li Wen-Liang, Chen Jian, Luo Mei-Hong, Lu Han, Ma Li, Li Wei-Lin
Affiliation:
Keywords: Glycogen phosphorylase, inhibitors, binding sites, type 2 diabetes, allosteric protein, metabolism, gluconeogenesis, cyclodextrins, van der Waals bonds, riboflavin
Abstract:
Glycogen phosphorylase (GP) has been firmly proved as an important target for treatment of type 2 diabetes. With the rapid increase of type 2 diabetic patients recently, it is becoming an interesting field to discover GP inhibitor for potential antidiabetic drugs. As GP is a typical allosteric protein with several key inhibitor binding sites including the inhibitor, the catalytic, the allosteric and the new allosteric sites, the research works were mainly focused on compounds that can bind these sites and show selective inhibitory effect. This paper mainly reviewed the advances in the design of inhibitors for different binding sites of GP and aimed at providing readers with some useful hints towards more effective GP inhibitors.
Export Options
About this article
Cite this article as:
Li Wen-Liang, Chen Jian, Luo Mei-Hong, Lu Han, Ma Li, Li Wei-Lin , Recent Advances in Design of Glycogen Phosphorylase Inhibitors, Current Enzyme Inhibition 2011; 7 (4) . https://dx.doi.org/10.2174/157340811799860533
DOI https://dx.doi.org/10.2174/157340811799860533 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Endocarditis Due to Salmonella Enterica Subsp. Arizonae in a Patient with Sickle Cell Disease: A Case Report and Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews Prevention of Endothelial Dysfunction and Cardiovascular Disease by n-3 Fatty Acids-Inhibiting Action on Oxidative Stress and Inflammation
Current Pharmaceutical Design Coffee to Reduce Risk of Type 2 Diabetes? : A Systematic Review
Current Diabetes Reviews Flavonoids as Promising Lead Compounds in Type 2 Diabetes Mellitus: Molecules of Interest and Structure-Activity Relationship
Current Medicinal Chemistry Emerging Therapies for Type 2 Diabetes
Current Drug Therapy Glucose Lowering Activity of the Aqueous Extract of Warionia saharae in Normal and Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry GIP-Based Therapeutics for Diabetes and Obesity
Current Chemical Biology HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design L-Dopa Related Hyperhomocysteinemia: A Possible Mediator of Toxicity?
Letters in Drug Design & Discovery Therapy of Chronic Hepatitis C in the Era of Nanotechnology: Drug Delivery Systems and Liver Targeting
Mini-Reviews in Medicinal Chemistry Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Current Drug Delivery Anti-VEGF Molecules for the Management of Diabetic Macular Edema
Current Pharmaceutical Design Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets